GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Partnering to build biosynthesis processes and a pharmaceutical production platform
It is a novel oral NLRP3 inflammasome inhibitor
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
